IRIS
MINOTTI, GIORGIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 7.805
NA - Nord America 1.574
EU - Europa 792
SA - Sud America 340
AF - Africa 37
OC - Oceania 33
Totale 10.581
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 5.674
US - Stati Uniti d'America 1.483
CN - Cina 907
HK - Hong Kong 897
BR - Brasile 254
GB - Regno Unito 238
VN - Vietnam 136
DE - Germania 134
IT - Italia 91
CZ - Repubblica Ceca 72
IN - India 57
NL - Olanda 53
CA - Canada 46
AR - Argentina 36
MX - Messico 34
FI - Finlandia 33
RU - Federazione Russa 33
AU - Australia 32
ID - Indonesia 27
JP - Giappone 26
BE - Belgio 22
UA - Ucraina 18
TR - Turchia 16
ZA - Sudafrica 16
PL - Polonia 14
EC - Ecuador 12
ES - Italia 12
FR - Francia 12
PY - Paraguay 12
BD - Bangladesh 9
SE - Svezia 9
CO - Colombia 8
EE - Estonia 8
CL - Cile 7
IQ - Iraq 7
LT - Lituania 6
TW - Taiwan 6
AE - Emirati Arabi Uniti 5
PE - Perù 5
TN - Tunisia 5
AL - Albania 4
HU - Ungheria 4
MY - Malesia 4
PT - Portogallo 4
RO - Romania 4
UZ - Uzbekistan 4
VE - Venezuela 4
AT - Austria 3
HR - Croazia 3
JO - Giordania 3
NA - Namibia 3
PK - Pakistan 3
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BY - Bielorussia 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
EG - Egitto 2
GE - Georgia 2
IE - Irlanda 2
IL - Israele 2
IR - Iran 2
KN - Saint Kitts e Nevis 2
KZ - Kazakistan 2
MA - Marocco 2
NG - Nigeria 2
NP - Nepal 2
PA - Panama 2
PH - Filippine 2
SI - Slovenia 2
UY - Uruguay 2
AG - Antigua e Barbuda 1
AM - Armenia 1
AO - Angola 1
BF - Burkina Faso 1
CH - Svizzera 1
CV - Capo Verde 1
CY - Cipro 1
DK - Danimarca 1
DM - Dominica 1
GA - Gabon 1
GT - Guatemala 1
IS - Islanda 1
KR - Corea 1
KW - Kuwait 1
LK - Sri Lanka 1
LV - Lettonia 1
MG - Madagascar 1
MR - Mauritania 1
NZ - Nuova Zelanda 1
OM - Oman 1
RS - Serbia 1
SA - Arabia Saudita 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
YE - Yemen 1
ZM - Zambia 1
Totale 10.581
Salva come PNG Salva come JPEG
Città #
Hong Kong 888
Singapore 638
Hefei 454
Ashburn 332
Boardman 268
London 204
Shanghai 145
Beijing 144
Dallas 112
Munich 71
Council Bluffs 64
Los Angeles 62
San Francisco 59
Redmond 56
Brno 54
Ho Chi Minh City 49
Amsterdam 41
Rome 35
Pune 34
Santa Clara 33
São Paulo 30
Toronto 28
Hanoi 24
New York 22
Washington 22
Mexico City 21
Seattle 20
Brooklyn 19
Turku 19
Melbourne 17
Olomouc 17
Hasselt 16
West Jordan 16
Tokyo 15
Helsinki 14
Chicago 13
Haiphong 13
Warsaw 12
Boston 11
Guangzhou 11
Canberra 10
Manchester 9
Phoenix 9
Atlanta 8
Chennai 8
Fortaleza 8
Johannesburg 8
Quito 8
Rio de Janeiro 8
Biên Hòa 7
Asunción 6
Buenos Aires 6
Haikou 6
Ankara 5
Bengaluru 5
Brasília 5
Hanover 5
Lima 5
New Delhi 5
Oklahoma City 5
Paris 5
Stockholm 5
Sydney 5
Belo Horizonte 4
Blumenau 4
Campinas 4
Catania 4
Charlotte 4
Curitiba 4
Da Nang 4
Ha Long 4
Hangzhou 4
Montreal 4
Moscow 4
Shenzhen 4
St Petersburg 4
Sulaymaniyah 4
Tashkent 4
Tenri 4
The Dalles 4
Tirana 4
Almere Stad 3
Amman 3
Bogotá 3
Budapest 3
Central 3
Dunstable 3
Franca 3
Genoa 3
Guarulhos 3
Ivanovo 3
Limeira 3
Mol 3
Ninh Bình 3
Nizhniy Novgorod 3
North Liberty 3
Petaling Jaya 3
Poplar 3
Praia Grande 3
Salvador 3
Totale 4.383
Salva come PNG Salva come JPEG
Nome #
Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. 204
Proceedings of an International Workshop on Anthracycline Cardiotoxicity 188
Anthracyclines and Cardiotoxicity: Is CARP a Forgotten Biomarker? 186
Cell Biology and Toxicology: Special Issue on Cardiovascular Liability of Drugs 185
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life 185
Cancer drugs and QT prolongation: weighing risk against benefit 184
Minimal sampling colistin pharmacokinetics in critically ill patients 183
An investigation into thee mechanism of citrateFE2+-dependent lipid peroxidation 181
Doxorubicinolone formation and efflux : A salvage pathway against epirubicin accumulation in human heart 177
A supposed role for superoxide dismutase in the control of tumor growth 176
The endogenous lusitropic and chronotropic agent, B-type natriuretic peptide, limits cardiac troponin release in cancer patients with an early impairment of myocardial relaxation induced by anthracyclines 174
A Special Section on Clinical Pharmacology-Editorial 171
Altered iron regulatory protein activities in doxorubicin-treated cardiomyocytes : Distinct roles of reactive oxygen species and of the secondary alcohol metabolite doxorubicinol 171
Cardiovascular toxicity of antitumor drugs :Translating molecular mechanisms into clinical facts 170
Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial 170
Heart Rate reduction by IVabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study. 169
Cardio-oncology in clinical studies and real life 168
Defective taxane stimulation of epirubicinol formation in the human heart: Insights into the cardiac tolerability of epirubicin-taxane chemotherapies 162
Acute Heart Failure 29 Years After Treatment for Childhood Cancer 161
Anthracycline cardiotoxicity in breast cancer patients: Synergism with trastuzumab and taxanes 156
Adriamycin dependent release of iron from human lung tumor microsomes : Biochemical mechanisms and clinical implications 155
4’- Epidoxorubicin to reexplore anthracycline degradation in cardiomyocytes 154
Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity 138
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology 123
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines 120
Pharmacology of cardio-oncology: chronotropic and lusitropic effects of B-type natriuretic peptide in cancer patients with early diastolic dysfunction induced by anthracycline or nonanthracycline chemotherapy 106
Anthracyclines 105
Anthracycline Cardiotoxicity 104
Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study 100
Anthracycline metabolism and toxicity in human myocardyum: Comparisons between doxorubicin, epirubicin, and a novel disaccaride analogue with redeced formation and [4Fe-4S]-reactivity of its secondary alchol metabolite 98
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival 97
Anthracycline Cardiotoxicity 89
Activation of heme oxygenase and consequent carbon monoxide formation inhibits the release of arginine vasopressin from rat hypothalamic explants. Molecular linkage between heme catabolism and neuroendocrine function. Mol Brain Res. 86
Anthracycline cardiotoxicity 85
An Invitation from the Editors of Cardio-Oncology 84
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: Relative importance of vesicular sequestration and impaired efficiency of electron addition 84
Anthracycline metabolism and toxicity in human myocardium : Comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with reduced formation and [4Fe-4S]-reactivity of its secondary alcohol metabolite 84
Adriamycin dependent release of iron from microsomal membranes 80
All Eyes on Me, Please: Ocular Palonosetron for the Cancer Patient with Nausea and Vomiting 79
An introduction to the metabolic determinants of anthracycline cardiotoxicity 79
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). 79
Adriamycin alcohol dependent iron mobilization : A novel mechanism of adriamycin cardiotoxicity? 78
Cardiotoxicity of antitumor drugs 74
Cardiotoxicity of targeted cancer drugs: concerns, “The cart before the horse,” and lessons from trastuzumab 69
Low dose anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites 67
CARDIAC ANTHRACYCLINE ACCUMULATION AND B-TYPE NATRIURETIC PEPTIDE TO DEFINE RISK AND PREDICTORS OF CANCER TREATMENT RELATED EARLY DIASTOLIC DYSFUNCTION 63
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement 54
Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny 51
Anthracyclines: molecular advances and pharmacological developments in antitumor activity and cardiotoxicity 51
Anthracyclines, diastolic dysfunction and the road to heart failure in Cancer survivors: An untold story 50
Rethinking drugs from chemistry to therapeutic opportunities: Pixantrone beyond Anthracyclines. 47
Pharmacology of Cardio-Oncology 47
What is cardiotoxicity? 44
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin 42
Novel mechanisms for the inhibition of low density lipoprotein oxidation by ascorbic acid. 40
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach 39
Further analytical, pharmacokinetic, and clinical observations on low-dose ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia 39
Cardiotoxicity of antitumor drugs 39
Vitamin E inhibits enhanced F2 isoprostane biosynthesis in type IIA hypercholesterolemia excretion 38
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies 37
Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation: Implications for Cardiotoxicity of Anticancer Anthracyclines 37
Isavuconazole: case report and pharmacokinetic considerations 37
Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from low-dose doxorubicin 37
Development of a tumor-specific photoactivatable doxorubicin prodrug. 37
Doxorubicin toxicity in human heart: role of C-13 metabolite, c-aconitase and iron 37
Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion. 37
Nitric oxide and peroxynitrite activate the iron regulatory protein-1 of J774A.1 macrophages by direct disassembly of the Fe-S cluster of cytoplasmic aconitase 37
The [Fe-S] cluster of cytoplasmic aconitase as a novel target of anthracycline cardiotoxicity 36
Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma 36
Mechanisms and clinical course of cardiovascular toxicity of cancer treatment II. Hematology 35
Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium 35
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 35
The iron regulatory proteins: targets and modulators of free radical reactions and oxidative damage 35
Post-transcriptional control of hepatic oxidative stress respone 35
Silent myocardial ischaemia on cardiac SPECT with MIBI implies endotelian toxicity in cancer patients on multiagent chemotherapy 35
Quo Vadis COVID? Lessons from a Focus Topic Issue of Chemotherapy 35
Cancer incidence and mortality in patients diagnosed with heart failure: results from an updated systematic review and meta-analysis 34
Pixantrone: novel mode of action and clinical readouts. 34
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox 34
Cardiovascular Toxicity of non cardiovascular drugs 34
Predictors of early or delayed diastolic dysfunction after anthracycline-based or nonanthracycline chemotherapy: a pharmacological appraisal 34
Doxorubicin irreversibly inactivates Iron Regulatory Proteins 1 and 2 in cardiomyocytes : Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy 34
Safety and tolerability of a novel oral nutritional supplement in healthy volunteers 34
Platelets: the point of interconnection among cancer, inflammation and cardiovascular diseases 34
NEW TARGETED DRUGS FOR ACUTE MYELOID LEUKEMIA AND ANTIFUNGALS: PHARMACOKINETIC CHALLENGES AND OPPORTUNITIES 33
Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin 33
Anthracycline secondary alcohol metabolite formation in human or rabbit heart ; Biochemical aspects and pharmacological implications 33
Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin. Pharmacologic and molecular reappraisal of anthracycline cardiotoxicity 33
Cardio-oncological management of patients. 33
Efficacy of sodium-glucose cotransporter-2 inhibitors in heart failure patients treated with dual angiotensin receptor blocker-neprilysin inhibitor: An updated meta-analysis 33
Ibrutinib and Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias/sudden cardiac death 33
Beyond poisons and problems : Toxicology in Italy 32
Superoxide and hydrogen peroxide dependent inhibition of Iron Regulatory Protein activity : a protective stratagem against oxidative injury. 32
Early diagnosis of acute coronary syndrome. 32
Doxorubicin-Dexrazoxane from day 1 for soft-tissue sarcomas: The road to cardioprotection 32
Matters of the heart: The case of TNF-alpha targeting drugs 31
The concomitant management of cancer therapy and cardiac therapy 31
Iron delocalization as a mechanism of disease: the case of anthracycline cardiotoxicity 31
In vitro modelling of the structure-activity determinants of anthracycline cardiotoxicity 31
Mechanisms of anthracycline cardiotoxicity : proposal for a unifying hypothesis 31
Totale 7.981
Salva come PNG Salva come JPEG
Categoria #
all - tutte 96.381
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 96.381
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022527 0 5 0 1 0 1 2 214 7 7 7 283
2022/2023108 2 4 5 8 7 5 13 0 2 7 51 4
2023/2024776 22 87 29 55 96 329 9 29 6 24 10 80
2024/20257.426 150 67 268 29 72 168 91 32 690 586 2.541 2.732
2025/20261.922 714 289 311 608 0 0 0 0 0 0 0 0
Totale 10.759